department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Genprex, Inc. ($GNPX) · pharmadog

PUBLIC COMPANY

$GNPXGenprex, Inc.

Austin, TX, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Preclinical1Phase 2

quaratusugene ozeplasmid

Non-Small Cell Lung Cancer

Type 1 Diabetes (Juvenile Diabetes)

Upcoming

no upcoming catalysts on record

Recent

(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Genprex, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$GNPX

SEC CIK

0001595248

country

US

source

sec_tickers

top tags

NSCLC1 Oncology1 Type 2 Diabetes1

mentioned in

0news items

entity-linker matched

$GNPX

Active trials

phase1Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancerterminatedn=5
phase2Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patientsrecruitingn=62
phase2Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinibrecruitingn=158

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 11m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$22

2 transactions

net (buys − sells)

−$22

non-derivative only

open-market buys + sells

Apr 14, 26SELLLONGNECKER BRENT M· director10 sh @ $1.23−$12↗
Apr 14, 26SELLLONGNECKER BRENT M· director8 sh @ $1.23−$10↗

routine RSU / option mechanics (2)

Feb 27, 26tax coverConfer Ryan M. · President, CEO and CFO9,330 sh
Feb 27, 26tax coverBerger Mark Stanley · Chief Medical Officer7,168 sh